bpc-157 periodontal clinical trial bpc 157 🦷 & TB-500: Experimental peptides showing preclinical promise for faster oral healing, reduced gum inflammation & bone support in animal studies. Not FDA-approved for dentistry — research only Peptides – Shores Dental Co.

Presented at: Consortium of Multiple Sclerosis Centers Annual Meeting

But those are different trials with different durations and doses, and cagrilintides strongest data are as the CagriSema combination, so any ranking is a cross-trial inference rather than a proven result

WADAs ban suggests that they could confer an advantagewhich also means there just may be something to them

A: Compounded formulations offer customizable concentrations (e.g., minoxidil above 5%), alternative delivery vehicles for patients with sensitivities, ingredients not available commercially as topicals (finasteride, dutasteride, spironolactone), and multi-agent combinations that address multiple hair loss mechanisms in a single application